Ann Oncol: The tissue pathological characteristics of pCR patients after the new complementary treatment of melanoma are associated with the occurrence of no recurrence.

Clinical trials have confirmed the safety and effectiveness of the new complementary treatments for dalavini and d-T in patients with BRAFV600E/K mutant melanoma who can be surgically removed.
that although pCR patients showed better no recurrence (RFS) than non-pCR patients, there was still a 30% risk of recurrence in pCR patients.
, a study published in Ann Oncol analyzed postoperative pathological characteristics in pCR patients and found differences in prognosis in pCR patients with different pathological characteristics.
To determine whether the histopathological characteristics of pathological responses can be used to assess relapse risk, the study reviewed and analyzed surgical excision specimens from patients with new complementary treatments in phase II clinical trials and evaluated the relationship between tissue pathological characteristics such as active tumors, necrosis, melanin composure, and relative number of fibrosis (transparency or immaturity/progenitority) and patient prognosis.
a total of 59 patients received new assisted surgical excision treatment from D-T.
patients who received pCR (49%) had a longer recurrence (RFS) than patients who did not reach pCR (P .005).
the tumors treated showed any glass fibrosis patients whose RFS was longer than patients without such pathological characteristics (P .014), while necrosis (P .012) and/or immature/permafic fibrosis (P .026) were associated with shorter RFS.
multivariable analysis shows that no pCR or the presence of immature fibrosis can independently predict shorter RFS.
in pCR patients, mature/transparent fibrosis was associated with RFS improvement (P .035).
study showed that the extent and composition of pathological responses after the new complementary treatment of BRAFV600E/K mutant melanoma D-T were associated with RFS, including in pCR patients.
these findings support a detailed histological analysis of specimens collected after the new complementary treatment.
.